About US
Contact us
-
UK study finds drug that could help treat aggressive breast cancersA study by researchers at The Institute of Cancer Research, London (ICR), has revealed that a drug, BOS172722, could help boost chemotherapy response in aggressive breast cancers that have become res2019/9/29
-
FDA approves self-administration of AstraZeneca’s asthma drugThe US Food and Drug Administration (FDA) has approved self-administration AstraZeneca’s asthma drug Fasenra, a pre-filled, single-use auto-injector. The FDA issued its approval based on the Phase II2019/9/29
-
Goldfinch acquires global rights to Takeda’s monoclonal antibodyUS-based clinical-stage biotechnology company Goldfinch Bio has entered an agreement with Japanese firm Takeda Pharmaceutical for global rights to a preclinical, peripherally restricted cannabinoid r2019/9/27
-
ViiV unveils emotional challenges related to HIV ART treatmentGSK’s ViiV Healthcare has presented results from its Positive Perspectives study examining the emotional challenges and burden of human immunodeficiency virus (HIV) antiretroviral therapy (ART) on pe2019/9/27
-
UK’s CMA accuses Aspen of price hike for Addison’s disease drugThe UK’s Competition and Markets Authority (CMA) has alleged that South Africa-based pharmaceutical company Aspen has entered an illegal agreement with Amilco and Tiofarma for marketing Addison’s dis2019/9/26
-
Gilead’s Descovy secures FDA approval for HIV preventionGilead Sciences has secured the US Food and Drug Administration (FDA) approval for Descovy in pre-exposure prophylaxis (PrEP) to mitigate the risk of sexually acquired HIV-1 infection. The drug is in2019/9/26
-
UK’s NICE rejects Roche’s Tecentriq for triple negative breast cancerThe UK’s National Institute for Health and Care Excellence (NICE) has rejected the first targeted immunotherapy treatment for people with triple negative breast cancer for use on the NHS. The cost wa2019/9/25
-
Keytruda approved in China as a monotherapy for NSCLCMerck has announced that Keytruda has been approved by the Chinese National Medical Products Administration (NMPA) as a monotherapy for first-line treatment of local advanced or metastatic non-small2019/9/25
-
Servier acquires non-Hodgkin lymphoma drug from CTI BioPharmaFrench pharmaceutical company Servier has purchased Pixuvri medicine, indicated for the treatment of non-Hodgkin B-cell lymphoma, from US-based CTI BioPharma. Financial details of the transaction are2019/9/24
-
Novartis teams up with Microsoft for AI drug developmentNovartis has allied with Microsoft to leverage the latter’s artificial intelligence (AI) technology for the discovery, development and commercialisation of medicines. Under the multi-year collaborati2019/9/24